NO20012526D0 - Sammensetninger som innbefatter cefuroksimaksetil - Google Patents

Sammensetninger som innbefatter cefuroksimaksetil

Info

Publication number
NO20012526D0
NO20012526D0 NO20012526A NO20012526A NO20012526D0 NO 20012526 D0 NO20012526 D0 NO 20012526D0 NO 20012526 A NO20012526 A NO 20012526A NO 20012526 A NO20012526 A NO 20012526A NO 20012526 D0 NO20012526 D0 NO 20012526D0
Authority
NO
Norway
Prior art keywords
oxetil
compositions
include cefuroxime
cefuroxime
cefuroxime oxetil
Prior art date
Application number
NO20012526A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012526L (no
Inventor
Herwig Jennewein
Johannes Raneburger
Original Assignee
Biochemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemie Gmbh filed Critical Biochemie Gmbh
Publication of NO20012526L publication Critical patent/NO20012526L/no
Publication of NO20012526D0 publication Critical patent/NO20012526D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
NO20012526A 1998-11-26 2001-05-23 Sammensetninger som innbefatter cefuroksimaksetil NO20012526D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
PCT/EP1999/009096 WO2000030647A1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil

Publications (2)

Publication Number Publication Date
NO20012526L NO20012526L (no) 2001-05-23
NO20012526D0 true NO20012526D0 (no) 2001-05-23

Family

ID=3525440

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012526A NO20012526D0 (no) 1998-11-26 2001-05-23 Sammensetninger som innbefatter cefuroksimaksetil

Country Status (30)

Country Link
US (1) US6727243B1 (cs)
EP (1) EP1133298B1 (cs)
JP (1) JP2002530338A (cs)
KR (1) KR20010080566A (cs)
CN (1) CN1330546A (cs)
AR (1) AR021405A1 (cs)
AT (3) AT413647B (cs)
AU (1) AU759517B2 (cs)
BR (1) BR9915694A (cs)
CA (1) CA2348876A1 (cs)
CO (1) CO5190668A1 (cs)
CZ (1) CZ20011845A3 (cs)
DE (1) DE69935609T2 (cs)
ES (1) ES2285866T3 (cs)
HU (1) HUP0104412A3 (cs)
ID (1) ID28615A (cs)
IL (1) IL142762A0 (cs)
MY (1) MY129564A (cs)
NO (1) NO20012526D0 (cs)
NZ (1) NZ511588A (cs)
PE (1) PE20001326A1 (cs)
PL (1) PL348744A1 (cs)
RU (1) RU2248794C2 (cs)
SI (1) SI1133298T1 (cs)
SK (1) SK7162001A3 (cs)
TR (1) TR200101417T2 (cs)
TW (1) TWI229603B (cs)
WO (1) WO2000030647A1 (cs)
YU (1) YU34601A (cs)
ZA (1) ZA200103927B (cs)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001230490A1 (en) * 2000-12-01 2002-06-11 Arun Shriniwas Gosavi Pharmaceutical formulation
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
ES2201932B2 (es) * 2001-11-23 2005-03-16 Glaxo Group Limited Composicion farmaceutica.
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
WO2004019901A2 (en) * 2002-08-30 2004-03-11 Orchid Chemicals & Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
KR100552567B1 (ko) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
NZ580951A (en) * 2005-04-29 2011-06-30 Cubist Pharm Inc Therapeutic compositions
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术(石家庄)有限公司 一种微囊化头孢呋辛酯的药物组合物
CA2800442C (en) 2010-06-14 2018-05-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
EP2882423A1 (en) * 2012-08-07 2015-06-17 Sandoz AG Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide
CA2910121A1 (en) 2013-04-25 2014-10-30 Kyorin Pharmaceutical Co., Ltd. A pharmaceutical composition comprising a 1,4-dihydroquinoline carboxylic acid a cellulosic excipient and a salting-out agent
CN105338982B (zh) 2013-04-25 2017-10-10 杏林制药株式会社 固体药用组合物
JP6018334B2 (ja) 2014-10-23 2016-11-02 杏林製薬株式会社 固形医薬組成物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1572993A (en) * 1976-02-16 1980-08-13 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
NL193682C (nl) * 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
DE19602757A1 (de) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
ES2565163T3 (es) * 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
CA2209868C (en) * 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
EP1066040B1 (en) * 1998-03-03 2003-02-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
CA2239331C (en) * 1998-05-29 1999-11-30 Bernard Charles Sherman Pharmaceutical tablets comprising cefuroxime axetil
DE19835823A1 (de) * 1998-08-10 1999-10-07 Lindopharm Gmbh Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
CZ20011845A3 (cs) 2001-08-15
ATA198998A (de) 2005-09-15
AT500135A1 (de) 2005-11-15
BR9915694A (pt) 2001-08-14
EP1133298B1 (en) 2007-03-21
DE69935609D1 (de) 2007-05-03
RU2248794C2 (ru) 2005-03-27
PE20001326A1 (es) 2000-12-12
YU34601A (sh) 2004-09-03
IL142762A0 (en) 2002-03-10
AR021405A1 (es) 2002-07-17
TR200101417T2 (tr) 2001-11-21
NZ511588A (en) 2003-08-29
NO20012526L (no) 2001-05-23
US6727243B1 (en) 2004-04-27
KR20010080566A (ko) 2001-08-22
WO2000030647A1 (en) 2000-06-02
AU1654400A (en) 2000-06-13
ID28615A (id) 2001-06-21
TWI229603B (en) 2005-03-21
PL348744A1 (en) 2002-06-03
DE69935609T2 (de) 2007-12-06
JP2002530338A (ja) 2002-09-17
SK7162001A3 (en) 2001-10-08
ATE357237T1 (de) 2007-04-15
AU759517B2 (en) 2003-04-17
ZA200103927B (en) 2002-05-15
CN1330546A (zh) 2002-01-09
SI1133298T1 (sl) 2007-10-31
EP1133298A1 (en) 2001-09-19
ES2285866T3 (es) 2007-11-16
HUP0104412A2 (hu) 2002-04-29
MY129564A (en) 2007-04-30
AT413647B (de) 2006-04-15
CA2348876A1 (en) 2000-06-02
HUP0104412A3 (en) 2002-08-28
CO5190668A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
ID26549A (id) Komposisi-komposisi epotilon
ATE367793T1 (de) Schweisshemmende zusammensetzungen
FI981011L (fi) Uudet koostumukset
BR9903578B1 (pt) composiÇÕes de toner.
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
ATE469550T1 (de) Antiparasitäre zusammensetzungen
DE69919953D1 (de) Funktionelle zusammensetzungen
PT1049467E (pt) Composicoes de celecoxib
NO20011738L (no) Heterocyclylaminometyloksazolidinoner som antibakterielle midler
TR199800375A3 (tr) Selant kompozisyonlari.
AR023440A1 (es) Composiciones antitranspirantes
DE69935172D1 (de) Imidosilan Zusammensetzungen
DE69903545D1 (de) Ölzusammensetzungen
NO20012526D0 (no) Sammensetninger som innbefatter cefuroksimaksetil
DE69914629D1 (de) Waschmittelzusammensetzungen
DE69915671D1 (de) Waschmittelzusammensetzungen
ATE257691T1 (de) Schweisshemmende zusammensetzungen
DK0975623T3 (da) Indazolamidforbindelser som sertoninerge midler
ID27889A (id) Komposisi-komposisi kopolimer polisiklik
DE69904534D1 (de) Schmierfettzusammensetzungen
DE69834750D1 (de) Feste reinigungszusammensetzungen
PT1124567E (pt) Composicoes tamponadas para dialise
ATE296323T1 (de) Polyisocyanatzusammensetzungen
DE69929223D1 (de) Reinigungsmittelzusammensetzungen
IT1302028B1 (it) Composizioni espandenti

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application